Cheryl Waters, MD
Neurology · New York, NYNPI 1356395446
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,136 of the $189,365 with a category attached, or 66.6%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.9%. Reporting peaked in 2019 at $103,813 and has fallen 96.7% since, to $3,446 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $942.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$43K
- Acadia Pharmaceuticals Inc$41K
- Neurocrine Biosciences, Inc.$29K
- MDD US Operations, LLC$24K
- Amneal Pharmaceuticals LLC$22K
- Kyowa Kirin, Inc.$10K
- plus $20K from 7 others
Across 67 payments — averaging $8607.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$357K
- Biogen$109K
- UCB SA$50K
- Sunovion Pharmaceuticals Inc.$43K
- Acorda Therapeutics, Inc$13K
- MDD US Operations, LLC$3K
- plus $2K from 1 others
What the payments were for
- Consulting fees$49,66326%
- Speaking & faculty fees$126,13667%
- Travel & lodging$10,2245%
- Food & beverage$3,3412%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acorda Therapeutics, Inc | 28 | $43,455 |
| Acadia Pharmaceuticals Inc | 44 | $40,687 |
| Neurocrine Biosciences, Inc. | 32 | $29,376 |
| MDD US Operations, LLC | 46 | $24,486 |
| Amneal Pharmaceuticals LLC | 23 | $21,782 |
| Kyowa Kirin, Inc. | 9 | $9,767 |
| Adamas Pharmaceuticals, Inc. | 10 | $8,744 |
| Tanabe Pharma America, Inc. | 1 | $5,500 |
| Lundbeck LLC | 2 | $2,500 |
| Kyowa Kirin Pharmaceutical Development, Inc | 1 | $1,875 |
| AbbVie | 3 | $1,105 |
| Eisai Inc. | 1 | $48 |
| Medtronic | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$189,365 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 79 | $556,586 |
| GocovriAmantadine Hcl | 74 | $226,345 |
| RytaryCarbidopa/Levodopa | 54 | $59,922 |
| InbrijaLevodopa | 12 | $51,071 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 902 | $41,143 |
| Droxidopa | 25 | $37,824 |
| NeuproRotigotine | 24 | $29,571 |
| XadagoSafinamide Mesylate | 11 | $17,836 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 323 | $14,150 |
| MyrbetriqMirabegron | 15 | $8,293 |
| Rivastigmine | 25 | $6,903 |
| AmantadineAmantadine Hcl | 89 | $4,132 |
| Rasagiline Mesylate | 31 | $3,261 |
| Orphenadrine Citrate ErOrphenadrine Citrate | 23 | $1,815 |
| Ropinirole ErRopinirole Hcl | 21 | $1,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $40,687 | $556,58679 claims |
| MDD US Operations, LLCGocovri | $24,486 | $226,34574 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $21,782 | $61,00074 claims |
| Acorda Therapeutics, IncInbrija | $43,455 | $51,07112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.